Department of Surgery, Medical School, Federal University of Ceará, Brazil.
Braz J Otorhinolaryngol. 2009 Jul-Aug;75(4):476-84. doi: 10.1016/S1808-8694(15)30483-3.
Cisplatin (cis-diamminedicloroplatinum) is an antineoplastic drug used in the treatment of a variety of cancers, especially head-and-neck cancer. Its ototoxicity, however, has been noted as a common side-effect which limits its use and causes significant morbidity.
to assess distortion-product otoacoustic emissions (DPOAE) and brainstem evoked response audiometry (BERA) sensitivity to detect secondary ototoxicity caused by different doses and means of administration of cisplatin in rats.
Experimental.
Male Wistar rats were intraperitoneally (i.p.) injected with 24 mg/kg cisplatin, divided into three equal doses (8 mg/kg) or a single i.p. injection of 16 mg/kg. The animals were evaluated by distortion product otoacoustic emission (DPOAE) or brainstem evoked response audiometry (BERA) on the 3rd and 4th days after the cisplatin injection.
Treatment with cisplatin 24 mg/kg resulted in significant DPOAE decrease and it raised the BERA electrophysiological threshold. The 16 mg/kg dose could not significantly reduce the DPOAE amplitude, but it raised the animals' hearing thresholds - detected by the BERA.
In rats, BERA was more sensitivity than DPOAE at detecting cisplatin-induced ototoxicity in rats considering different doses and means of administration.
顺铂（顺式二氨二氯铂）是一种用于治疗多种癌症的抗肿瘤药物，特别是头颈部癌症。然而，其耳毒性已被认为是一种常见的副作用，限制了其使用并导致严重的发病率。
评估畸变产物耳声发射（DPOAE）和脑干诱发电位测听（BERA）对检测不同剂量和给药方式顺铂引起的大鼠继发性耳毒性的敏感性。
实验性。
雄性 Wistar 大鼠腹腔内（i.p.）注射 24mg/kg 顺铂，分为三个相等剂量（8mg/kg）或单次腹腔注射 16mg/kg。在顺铂注射后的第 3 天和第 4 天，通过畸变产物耳声发射（DPOAE）或脑干诱发电位测听（BERA）评估动物。
24mg/kg 顺铂治疗导致 DPOAE 明显降低，并提高了 BERA 电生理阈值。16mg/kg 剂量不能显著降低 DPOAE 幅度，但提高了动物的听力阈值-通过 BERA 检测到。
在大鼠中，考虑到不同的剂量和给药方式，BERA 比 DPOAE 更能敏感地检测顺铂引起的大鼠耳毒性。
